Psychiatric Morbidity in Women With Previous Gestational Diabetes Mellitus: A Nationwide Register-Based Cohort Study.


Journal

Diabetes care
ISSN: 1935-5548
Titre abrégé: Diabetes Care
Pays: United States
ID NLM: 7805975

Informations de publication

Date de publication:
01 05 2023
Historique:
received: 11 10 2022
accepted: 24 02 2023
medline: 17 5 2023
pubmed: 18 3 2023
entrez: 17 3 2023
Statut: ppublish

Résumé

To investigate associations between previous gestational diabetes mellitus (GDM) and incident psychiatric morbidity, and to explore the role of subsequent diabetes development in psychiatric morbidity risk. A nationwide register-based cohort study including all women delivering in Denmark from 1997 to 2018 was conducted. GDM exposure was based on diagnosis code, whereas psychiatric morbidity outcome was based on diagnosis code and psychopharmacological medication use. Multiple Cox regression and mediation analyses were performed. In a study population of 660,017 women, previous GDM was associated with increased risk of depression based on diagnosis code and/or medication use (adjusted hazard ratio [aHR] 1.22 [95% CI 1.18-1.27]), any psychiatric diagnosis (aHR 1.20 [95% CI 1.13-1.27]), and any psychopharmacological medication use (aHR 1.21 [95% CI 1.17-1.25]). Moreover, risk of depressive and anxiety disorders, as well as antidepressant and antipsychotic medication use, was increased, with aHRs ranging from 1.14 (95% CI 1.05-1.25) to 1.32 (95% CI 1.22-1.42). No associations were found regarding substance use disorders, psychotic disorders, bipolar disorders, postpartum psychiatric disease, or anxiolytic medication use. Psychiatric morbidity risk was higher in women with versus without subsequent diabetes development. However, GDM history affected risk estimates only in women without subsequent diabetes. Subsequent diabetes mediated 35-42% of the associations between GDM and psychiatric morbidity. GDM was associated with increased psychiatric morbidity risk. Subsequent diabetes development played a significant role in future psychiatric morbidity risk after GDM, although it only partly explained the association.

Identifiants

pubmed: 36928320
pii: 148583
doi: 10.2337/dc22-1961
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1076-1084

Informations de copyright

© 2023 by the American Diabetes Association.

Auteurs

Maria Hornstrup Christensen (MH)

1Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark.
2Department of Gynecology and Obstetrics, Odense University Hospital, Odense, Denmark.
3Department of Clinical Research, University of Southern Denmark, Odense, Denmark.

Marianne Skovsager Andersen (MS)

3Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
4Department of Endocrinology, Odense University Hospital, Odense, Denmark.

Katrine Hass Rubin (KH)

5Research Unit Open Patient Data Explorative Network (OPEN), Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
6OPEN, Odense University Hospital, Odense, Denmark.

Ellen Aagaard Nohr (EA)

2Department of Gynecology and Obstetrics, Odense University Hospital, Odense, Denmark.
3Department of Clinical Research, University of Southern Denmark, Odense, Denmark.

Jori Aalders (J)

1Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark.
3Department of Clinical Research, University of Southern Denmark, Odense, Denmark.

Christina Anne Vinter (CA)

1Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark.
2Department of Gynecology and Obstetrics, Odense University Hospital, Odense, Denmark.
3Department of Clinical Research, University of Southern Denmark, Odense, Denmark.

Dorte Moeller Jensen (DM)

1Steno Diabetes Center Odense, Odense University Hospital, Odense, Denmark.
2Department of Gynecology and Obstetrics, Odense University Hospital, Odense, Denmark.
3Department of Clinical Research, University of Southern Denmark, Odense, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH